Pages that link to "Q71008927"

The following pages link to Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability (Q71008927):

Displaying 48 items.

• Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development (Q24646866) (← links)
• Accuracy of popular automatic QT interval algorithms assessed by a 'gold standard' and comparison with a Novel method: computer simulation study. (Q24814899) (← links)
• Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval (Q28345558) (← links)
• The effect of moxifloxacin on QTc and implications for the design of thorough QT studies (Q33411837) (← links)
• Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective (Q33590722) (← links)
• Cardiovascular safety of fexofenadine HCl. (Q33640024) (← links)
• Comparative tolerability of second generation antihistamines (Q33646897) (← links)
• Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential (Q33661043) (← links)
• Cardiac complications in the intensive care unit (Q33673754) (← links)
• Differences and similarities between chronic obstructive pulmonary disease and asthma (Q33696756) (← links)
• Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition (Q33834603) (← links)
• Drug-induced proarrhythmic effects: assessment of changes in QT interval (Q34049827) (← links)
• Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study (Q34259088) (← links)
• Drug-Induced Long QT Syndrome (Q34358104) (← links)
• Individual QT-R-R relationship: average stability over time does not rule out an individual residual variability: implication for the assessment of drug effect on the QT interval. (Q34412724) (← links)
• The significance of QT interval in drug development (Q34808276) (← links)
• Designing and interpreting the results of first-time-to-man studies (Q35236261) (← links)
• Does terfenadine‐induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? (Q36159074) (← links)
• On the relationship among QT interval, atrial fibrillation, and torsade de pointes (Q37008418) (← links)
• Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance (Q37012882) (← links)
• Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval (Q37154348) (← links)
• The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research (Q37473713) (← links)
• Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study (Q37624739) (← links)
• Thorough QT Studies: Questions and Quandaries (Q37650057) (← links)
• QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes (Q38081716) (← links)
• Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? (Q38082420) (← links)
• Predicting drug-induced QT prolongation and torsades de pointes (Q38667401) (← links)
• Keep the QT interval: it is a reliable predictor of ventricular arrhythmias (Q39018169) (← links)
• Murine Electrophysiological Models of Cardiac Arrhythmogenesis (Q39038606) (← links)
• Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. (Q39674138) (← links)
• Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs (Q40885464) (← links)
• The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys (Q41255343) (← links)
• Moving towards better predictors of drug-induced torsades de pointes (Q41255441) (← links)
• Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist (Q41592419) (← links)
• Changes in Repolarization Dynamicity and the Assessment of the Arrhythmic Risk (Q41633704) (← links)
• The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. (Q42687064) (← links)
• Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization (Q44582898) (← links)
• Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. (Q44844508) (← links)
• Electrocardiographic Findings in Patients With Diphenhydramine Overdose (Q51534405) (← links)
• Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. (Q53256610) (← links)
• The effect of pharmacokinetically guided acute intravenous testosterone administration on electrocardiographic and blood pressure variables (Q73072618) (← links)
• Non-sedating antihistamines and cardiac arrhythmia (Q73818286) (← links)
• Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen (Q77846726) (← links)
• Cardiac repolarization and the safety of new drugs defined by electrocardiography (Q79448430) (← links)
• Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval) (Q82243223) (← links)
• [Long QT syndrome. History, genetics, clinical symptoms, causes and therapy] (Q85849525) (← links)
• Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure (Q91297105) (← links)
• On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships (Q91863600) (← links)